In a recent study published in Nature Immunology, a team of researchers from the United States used non-human primate models to compare the protection conferred by an intramuscular booster dose of the bivalent messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccine with that provided by a booster dose of a mucosal bivalent adenoviral vector vaccine delivered through an aerosol device or intranasal route.
Background
The rapidly developed COVID-19 vaccines were successful in limiting the severity and transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, and the intramuscular booster doses continue to confer protection against high levels of morbidity and hospitalization.
However, studies have shown that the efficacy of intramuscularly administered bivalent mRNA vaccines vane after approximately four months, while breakthrough SARS-CoV-2 infections continue to occur.
Factors such as age, immunocompromised conditions, and post-acute sequelae could influence innate immunity levels and vaccine response, increasing the probability of breakthrough infections.
Vaccines that can prevent breakthrough infections would be effective in lowering the transmission levels and preventing the emergence of novel SARS-CoV-2 variants.
A mucosal vaccine, administered intranasally, could limit the transmission of SARS-CoV-2 by boosting the plasma cells and memory B cells in the lymphoid tissue associated with the mucosa and increasing the immune responses at the site of the infection.
About the study
In the present study, the researchers used Macaca mulatta or rhesus macaques to investigate the protective immune responses elicited by a mucosal bivalent adenoviral vector vaccine containing stabilized spike protein from the ancestral Wuhan strain and the Omicron BA.5 variant of SARS-CoV-2.
They compared these immune responses against those elicited by an intramuscular booster dose of a bivalent mRNA vaccine encoding the spike proteins of the same two variants.
Although the inflammation and pathology due to severe disease in humans are not completely recapitulated in non-human primate models, studies have shown that the virus readouts and immune responses observed in non-human primate models can be used to predict the clinical outcomes for Omicron infections in humans.
The adenoviral vector vaccine used in the study was the ChAd-SARS-CoV-2-S vaccine, which is currently being administered in the form of nasal drops in India under the name iNCOVACC. Viral vector vaccines using adenovirus, Newcastle disease virus, or parainfluenza virus can elicit immune responses at the site of the infection, making these vaccines an ideal candidate for a mucosal, intranasally administered booster dose.
The rhesus macaques in the study were primed with two intramuscular doses of an mRNA vaccine encoding the spike protein from the ancestral Wuhan strain.
Seven months after they were primed, one group of macaques was administered with the bivalent ChAd-SARS-CoV-2-S vaccine through an aerosol device, and the vaccine was delivered to the lower and upper airways.
A second group was administered the vaccine intranasally in the form of a mist using a clinical sprayer. In contrast, a comparison group was intramuscularly administered a booster dose of the bivalent mRNA vaccine.
The protection conferred by the mucosal adenoviral vector vaccine administered through aerosol and intranasal routes and the intramuscular booster dose of the bivalent mRNA vaccine were compared by challenging the animals with the XBB.1.16 strain of the virus four and a half months after the booster doses were administered.
Results
The study found that the viral replication in the lungs and the nose of the animals that were administered the mucosal adenoviral vector vaccine against SARS-CoV-2 was minimal for the animals in both the aerosol and intranasal administration groups.
In contrast, the animals that were intramuscularly administered the booster dose of the bivalent mRNA vaccine showed lower levels of viral replication only in the lower airways.
The mucosal vaccine also resulted in durable immunoglobulin (Ig) A and IgG responses in the airways and activated B cells specific for the spike protein in the lungs, which was not observed in the case of the intramuscular bivalent mRNA vaccine booster dose.
The study found that the aerosolized delivery of the mucosal vaccine elicited broad mucosal immunity in multiple respiratory compartments, which could rapidly suppress the replication of SARS-CoV-2.
In comparison, the intranasally administered booster dose of the same vaccine could only boost the IgA titers in the airway, which could prevent the local replication of the virus but could not inhibit viral replication in the lungs as effectively as the aerosolized booster dose or elicit memory B cells specific to the spike protein.
Conclusions
Overall, the findings showed that a booster dose of mucosal adenoviral vector vaccine against SARS-CoV-2, administered as an aerosol, was most effective in controlling viral replication in the lungs and the nose.
The IgA titers in the airways were indicative of the protection in the upper respiratory compartments. In contrast, memory B cell and T cell responses, as well as IgA and IgG titers, correlated with the protection conferred in the lower airways.
- Gagne, M., Flynn, B.J., Andrew, S.F., Marquez, J., Flebbe, D.R., Mychalowych, A., Lamb, E., DavisGardner, M.E., Burnett, M.R., Serebryannyy, Leonid A, Lin, B.C., Ziff, Z.E., Maule, E., Carroll, R., Naisan, M., Jethmalani, Y., Pessaint, L., Todd, J.M., DoriaRose, N.A. & Case, J.B. (2024). Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates. Nature Immunology. doi:10.1038/s41590024019515. https://www.nature.com/articles/s41590-024-01951-5
News
Cutting Two Amino Acids Slowed Prostate Cancer in Mice
A newly identified link between amino acid metabolism and cholesterol production may help prostate tumors adapt to hormone therapy. Prostate cancer can find ways around treatments designed to deprive tumors of the hormones they [...]
Largest-Ever Physics Survey Raises New Doubts About Our Model of the Universe
Physicists around the world remain deeply divided on key mysteries of the universe, from dark matter to quantum gravity. The standard cosmological model failed to gain majority support, and no leading theory dominated the [...]
Scientists Just Overturned a 100-Year-Old Belief About Bacteria in the Lungs
New findings raise questions about the role of microbes living in the lungs. More than 35 trillion bacteria live throughout the human body, forming microbiomes in the gut, mouth, lungs, skin, and urogenital tract. [...]
GHCE Concept
From the preface of the book Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artificial Intelligence, Edited by Frank Boehm: Since the publication of my first book (Nanomedical Device and Systems [...]
Novartis, Ionis drug failure spurs questions
Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a result with important implications for cardiovascular drug research. Dive Brief: An RNA drug from [...]
New injectable treatment helps the brain rebuild after stroke
Biomedical engineers at Duke University have created an injectable biomaterial that may help the brain recover from damage left behind by an ischemic stroke. In experiments with mice, the material transformed the cavity created [...]
Scientists Discover a Hidden “Immune Organ” Inside the Skull
Researchers discovered lymph node-like immune hubs inside skull bone marrow that appear to act as rapid-response centers for the brain. For decades, the brain was thought to operate largely apart from the immune system. [...]
Engineered tRNAs and lipid nanoparticles target nonsense mutation cystic fibrosis
Researchers have developed a potential new approach for treating a form of cystic fibrosis caused by so-called nonsense mutations, combining chemically modified transfer RNAs with lipid nanoparticles designed to deliver the therapy directly to [...]
New pancreatic cancer drug carries a $39,800 monthly list price
A groundbreaking treatment for one of the most common forms of pancreatic cancer has been approved in pill form by the FDA. Revolution Medicines’ oral tablet daraxonrasib, branded as Rasonque, reduced the risk of [...]
Researchers Have Discovered a New Way To Reduce Chronic Nerve Pain
A cancer-linked protein called BRAF may help drive chronic nerve pain, and existing cancer drugs targeting it reduced pain sensitivity in preclinical models. Chronic nerve pain can persist long after an injury and often [...]
Our books now available worldwide!
Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]
Quantum-Enabled Regenerative Health: Reimagining Wellness, Precision Health and Longevity Medicine
Introduction Healthcare is approaching a frontier where the quantum portfolio could influence not only how disease is diagnosed and treated, but how health itself is measured, modeled, predicted and preserved. Quantum computing, quantum simulation, [...]
FDA Clears First-of-Its-Kind Nonmedication Treatment for PTSD
The FDA has cleared a system that uses brain activity data to personalize magnetic stimulation for PTSD, adding a new nonmedication treatment option. Every day in the United States, approximately 17.5 veterans die by suicide, [...]
FDA approves breakthrough drug to treat advanced pancreatic cancer
The Food and Drug Administration (FDA) approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer. The drug, called daraxonrasib, will be sold under the brand name Rasonque [...]
AI Decodes a Hidden DNA Signal Linked to Disease-Causing Mutations
Machine learning identifies the likely “initiator” and enables new predictions about DNA mutations that can cause disease. Every human cell depends on tens of thousands of genes being switched on at the right time [...]
Pope Leo Urges Global Response to Congo’s Deadliest Ebola Outbreak
Pope Leo called for international action to address the Ebola outbreak in the Democratic Republic of Congo. The epidemic has claimed over 2,500 lives and is the nation's largest recorded outbreak. The Pope emphasized [...]
